PI3K/AKT/mTOR inhibitors in ovarian cancer

M. Mazzoletti, M. Broggini

Research output: Contribution to journalArticlepeer-review


Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathway's activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew we'll try to discuss the published data of the inhibitors targeting members of the PI3K/akt/mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.

Original languageEnglish
Pages (from-to)4433-4447
Number of pages15
JournalCurrent Medicinal Chemistry
Issue number36
Publication statusPublished - Dec 2010


  • Anti-cancer drugs
  • Drug combination
  • mTOR
  • PI3K

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'PI3K/AKT/mTOR inhibitors in ovarian cancer'. Together they form a unique fingerprint.

Cite this